The application describes previous studies in which systemic priming of rhesus macaques with formalin-inactivated whole SIV in microspheres, followed by oral or intratracheal boosting with the microencapsulated vaccine, resulted in significant protection against intravaginal challenge with live pathogenic SIV. The application also describes various proposed approaches to improve upon mucosal immunization including: (1) utilizing recombinant vaccinia virus expression systems for the production of non-infectious virus-like particles (VLP's) to be used as antigens in microencapsulated vaccines, (2) developing recombinant baculovirus expression systems for expression of SIV and HIV virus-like particles, and (3) developing approaches for mucosal immunization with non-replicating plasmids encoding HIV and SIV antigens. (Adapted from the Application).
| Ishizaka, S T; Israel, Z R; Gettie, A et al. (1999) Induction of mucosal antibody responses by microsphere-encapsulated formalin-inactivated simian immunodeficiency virus in a male urethral challenge model. Vaccine 17:2817-25 |
| Sodora, D L; Sheridan, K E; Marx, P A et al. (1999) Immunization with a live, attenuated simian immunodeficiency virus vaccine leads to restriction of viral diversity in Rhesus macaques not protected from pathogenic challenge. J Virol 73:4443-6 |
| Smith, S M; Holland, B; Russo, C et al. (1999) Retrospective analysis of viral load and SIV antibody responses in rhesus macaques infected with pathogenic SIV: predictive value for disease progression. AIDS Res Hum Retroviruses 15:1691-701 |
